Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report) have earned a consensus rating of “Buy” from the six ratings firms that are presently covering the firm, Marketbeat reports. Six research analysts have rated the stock with a buy rating. The average 12 month price target among analysts that have issued a report on […]